How I treat myelofibrosis after failure of JAK inhibitors.

Pardanani, Animesh; Tefferi, Ayalew

Pardanani, Animesh; Tefferi, Ayalew.

Affiliation

Pardanani A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Tefferi A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

Blood ; 132(5): 492-500, 2018 08 02.

Article in En | MEDLINE | ID: mdl-29866811

Subject(s)

Janus Kinase 2/antagonists & inhibitors; Janus Kinase Inhibitors/adverse effects; Primary Myelofibrosis/drug therapy; Quality of Life; Salvage Therapy; Splenomegaly/chemically induced; Aged; Female; Humans; Janus Kinase 2/genetics; Male; Middle Aged; Mutation; Splenomegaly/drug therapy; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Splenomegaly / Salvage Therapy / Janus Kinase 2 / Primary Myelofibrosis / Janus Kinase Inhibitors Aspects: Patient_preference Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Blood Year: 2018 Document type: Article

Fulltext

XML

PubMed Links

Search on Google